CStone Pharmaceuticals (HK:2616)
:2616
Want to see HK:2616 full AI Analyst Report?
2616 Stock Chart & Stats
HK$5.34
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$5.34
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$3.91 - HK$13.15
Previous CloseN/A
Volume1.16M
Average Volume (3M)19.75M
Market Cap
HK$6.85B
Enterprise ValueHK$10.71B
Total Cash (Recent Filing)HK$919.09M
Total Debt (Recent Filing)HK$348.67M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Aug 20, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding1,600,249,100
10 Day Avg. Volume13,736,900
30 Day Avg. Volume19,747,038
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)10.65
Price to Sales (P/S)24.38
P/FCF Ratio-20.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$9.44Price Target Upside76.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)HK$461.53M
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA sharp 2025 revenue rebound indicates improving commercial execution and demand for marketed therapies. If sustained, stronger top-line growth supports scaling commercial infrastructure, funds pipeline progression, and creates optionality for margin recovery and reduced reliance on external financing over the next several quarters.
Improved LeverageLower debt-to-equity reduces near-term refinancing pressure and improves capital structure resilience. Moderate leverage gives management more flexibility to fund R&D and commercial activities, lowering bankruptcy risk and extending runway while the company pursues regulatory and commercialization milestones.
Diversified MonetizationA business model combining product sales, licensing, and collaboration revenues diversifies cash sources. Milestones and royalties can provide non-linear, high-margin cash inflows when partners advance programs, reducing single-product concentration risk and improving long-term revenue durability if partnerships deliver.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow means the business relies on external financing to fund operations and trials. This persistent cash burn raises dilution and refinancing risk, constraining strategic choices and potentially delaying development or commercialization if capital markets tighten over the coming months.
Margin DeteriorationA dramatic gross- and net-margin collapse signals structural cost or mix issues that impair the path to profitability. Such volatile margins hinder sustainable operating leverage, make forecasting cash needs harder, and reduce the likelihood of self-funding growth absent meaningful margin improvement.
Negative Returns On EquityDeeply negative ROE reflects severe capital inefficiency and that invested equity is not producing returns. Over time this erodes shareholder value, limits the company's ability to rebuild retained capital organically, and increases dependence on external capital which can be costly or dilutive.
CStone Pharmaceuticals News
2616 FAQ
What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$3.91 and its highest was HK$13.15 in the past 12 months.
What is CStone Pharmaceuticals’s market cap?
CStone Pharmaceuticals’s market cap is HK$6.85B.
When is CStone Pharmaceuticals’s upcoming earnings report date?
CStone Pharmaceuticals’s upcoming earnings report date is Aug 20, 2026 which is in 70 days.
How were CStone Pharmaceuticals’s earnings last quarter?
CStone Pharmaceuticals released its earnings results on Mar 26, 2026. The company reported -HK$0.138 earnings per share for the quarter, missing the consensus estimate of -HK$0.057 by -HK$0.08.
Is CStone Pharmaceuticals overvalued?
According to Wall Street analysts CStone Pharmaceuticals’s price is currently Undervalued.
Does CStone Pharmaceuticals pay dividends?
CStone Pharmaceuticals does not currently pay dividends.
What is CStone Pharmaceuticals’s EPS estimate?
CStone Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does CStone Pharmaceuticals have?
CStone Pharmaceuticals has 1,600,249,100 shares outstanding.
What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
CStone Pharmaceuticals reported an EPS of -HK$0.138 in its last earnings report, missing expectations of -HK$0.057. Following the earnings report the stock price went up 0.145%.
Which hedge fund is a major shareholder of CStone Pharmaceuticals?
Currently, no hedge funds are holding shares in HK:2616
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CStone Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
290.90%
12-Months-Change
Fundamentals
Return on Equity
-64.78%
Trailing 12-Months
Asset Growth
2.02%
Trailing 12-Months
Company Description
CStone Pharmaceuticals
CStone Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development, and commercialization of advanced immuno-oncology and precision medicines. Its mission is to address critical unmet medical needs for cancer patients, both within China and across the globe. The company's market-ready portfolio includes Sugemalimab, a monoclonal antibody targeting programmed death ligand 1 (PD-L1); GAVRETO, an RET inhibitor approved for advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor used to treat adults with unresectable or metastatic gastrointestinal stromal tumors featuring a PDGFRA exon 18 mutation. CStone also maintains a strong pipeline of investigational therapies, such as Nofazinlimab (a PD-1 antibody for hepatocellular carcinoma), Ivosidenib (an isocitrate dehydrogenase 1 (IDH1) inhibitor for adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation), and Fisogatinib (an FGFR4 inhibitor for hepatocellular carcinoma). Additional pipeline assets include CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500, primarily for solid tumors, along with CS5001, intended for both solid and hematologic malignancies. Established in 2015, CStone Pharmaceuticals is headquartered in Shanghai, China.
2616 Stock 12 Month Forecast
Average Price Target
HK$9.44
▲(76.78% Upside)
Technical Analysis
Zai Lab Ltd
―
Alphamab Oncology
―
InnoCare Pharma Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―
Options Prices
Currently, No data available
---